Stoke Therapeutics Key Executives
This section highlights Stoke Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Stoke Therapeutics
(Showing 0 of )
Stoke Therapeutics Earnings
This section highlights Stoke Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Stoke Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $36.55M | $8.78M | $12.40M | $- | $- |
| Cost of Revenue | $- | $- | $3.54M | $2.23M | $1.93M |
| Gross Profit | $36.55M | $8.78M | $8.87M | $-2.23M | $-1.93M |
| Gross Profit Ratio | 100.00% | 100.00% | 71.50% | - | - |
| Research and Development Expenses | $89.13M | $82.23M | $77.84M | $54.17M | $32.20M |
| General and Administrative Expenses | $48.79M | $41.32M | $38.92M | $31.90M | $20.85M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $48.79M | $41.32M | $38.92M | $31.90M | $20.85M |
| Other Expenses | $- | $- | $167.00K | $140.00K | $57.00K |
| Operating Expenses | $137.93M | $123.55M | $116.76M | $86.06M | $53.04M |
| Cost and Expenses | $137.93M | $123.55M | $116.76M | $86.06M | $53.04M |
| Interest Income | $- | $- | $3.12M | $120.00K | $744.00K |
| Interest Expense | $- | $- | $3.12M | $120.00K | $- |
| Depreciation and Amortization | $- | $2.47M | $3.54M | $2.23M | $1.93M |
| EBITDA | $-101.37M | $-112.30M | $-102.81M | $-83.58M | $-50.32M |
| EBITDA Ratio | -277.31% | -1279.09% | -828.78% | - | - |
| Operating Income | $-101.37M | $-114.77M | $-104.36M | $-86.06M | $-53.04M |
| Operating Income Ratio | -277.31% | -1307.21% | -841.24% | - | - |
| Total Other Income Expenses Net | $12.39M | $10.07M | $3.29M | $260.00K | $801.00K |
| Income Before Tax | $-88.98M | $-104.70M | $-101.07M | $-85.81M | $-52.24M |
| Income Before Tax Ratio | -243.42% | -1192.47% | -814.73% | - | - |
| Income Tax Expense | $- | $- | $-7.96M | $-1.09M | $-1.63M |
| Net Income | $-88.98M | $-104.70M | $-93.11M | $-84.71M | $-50.61M |
| Net Income Ratio | -243.42% | -1192.47% | -750.58% | - | - |
| EPS | $-1.65 | $-2.38 | $-2.39 | $-2.31 | $-1.51 |
| EPS Diluted | $-1.65 | $-2.38 | $-2.39 | $-2.31 | $-1.51 |
| Weighted Average Shares Outstanding | 54.01M | 43.99M | 38.90M | 36.74M | 33.49M |
| Weighted Average Shares Outstanding Diluted | 54.01M | 43.99M | 38.90M | 36.74M | 33.49M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.61M | $4.89M | $4.83M | $4.22M | $2.80M | $3.31M | $-2.48M | $5.15M | $3.27M | $2.90M | $3.23M | $3.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $1.11M | $1.11M | $1.11M | $1.22M | $1.20M | $1.17M | $1.15M | $1.15M | $924.00K | $835.00K | $624.00K | $621.00K | $576.00K | $526.00K | $507.00K | $- | $- | $- | $- |
| Gross Profit | $22.61M | $3.78M | $3.72M | $3.10M | $1.59M | $2.11M | $-3.65M | $4.00M | $2.12M | $1.98M | $2.40M | $2.38M | $-621.00K | $-576.00K | $-526.00K | $-507.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 100.00% | 77.30% | 77.02% | 73.60% | 56.64% | 63.72% | 147.04% | 77.74% | 64.76% | 68.19% | 74.16% | 79.20% | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $23.42M | $22.20M | $20.59M | $21.80M | $21.15M | $20.27M | $20.55M | $19.63M | $21.06M | $20.11M | $18.36M | $18.31M | $15.80M | $14.36M | $14.10M | $9.91M | $8.90M | $8.11M | $7.97M | $7.21M |
| General and Administrative Expenses | $12.84M | $12.69M | $13.04M | $10.22M | $10.61M | $10.27M | $10.23M | $10.21M | $9.38M | $9.94M | $10.11M | $9.49M | $8.72M | $8.32M | $7.93M | $6.91M | $5.68M | $5.60M | $5.04M | $4.52M |
| Selling and Marketing Expenses | $- | $- | $-562.00K | $-550.00K | $-591.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $12.84M | $12.69M | $12.47M | $9.67M | $10.02M | $10.27M | $10.23M | $10.21M | $9.38M | $9.94M | $10.11M | $9.49M | $8.72M | $8.32M | $7.93M | $6.91M | $5.68M | $5.60M | $5.04M | $4.52M |
| Other Expenses | $- | $- | $-48.00K | $-428.00K | $41.00K | $41.00K | $41.00K | $42.00K | $41.00K | $42.00K | $42.00K | $42.00K | $42.00K | $42.00K | $28.00K | $16.00K | $15.00K | $16.00K | $3.00K | $22.00K |
| Operating Expenses | $36.27M | $34.90M | $33.06M | $31.48M | $31.17M | $30.54M | $30.78M | $29.84M | $30.44M | $30.05M | $28.47M | $27.80M | $24.53M | $22.68M | $22.03M | $16.83M | $14.59M | $13.71M | $13.01M | $11.73M |
| Cost and Expenses | $36.27M | $34.90M | $34.17M | $32.59M | $32.39M | $30.54M | $30.78M | $29.84M | $30.44M | $30.05M | $28.47M | $27.80M | $24.53M | $22.68M | $22.03M | $16.83M | $14.59M | $13.71M | $13.01M | $11.73M |
| Interest Income | $- | $- | $- | $- | $2.59M | $2.65M | $2.57M | $2.10M | $1.48M | $995.00K | $544.00K | $- | $36.00K | $- | $34.00K | $18.00K | $10.00K | $11.00K | $50.00K | $674.00K |
| Interest Expense | $- | $- | $3.69M | $2.43M | $2.59M | $2.65M | $2.57M | $2.10M | $1.48M | $995.00K | $544.00K | $104.00K | $- | $44.00K | $34.00K | $12.00K | $- | $12.00K | $11.00K | $- |
| Depreciation and Amortization | $526.00K | $- | $1.11M | $1.11M | $1.22M | $1.20M | $1.17M | $1.15M | $1.15M | $924.00K | $835.00K | $624.00K | $621.00K | $576.00K | $526.00K | $507.00K | $237.00K | $234.00K | $224.00K | $193.00K |
| EBITDA | $-13.13M | $-30.00M | $-28.79M | $-27.81M | $-28.96M | $-26.60M | $-32.65M | $-24.09M | $-26.57M | $-26.76M | $-24.94M | $-24.55M | $-24.29M | $-22.43M | $-21.78M | $-16.59M | $-14.35M | $-13.48M | $-12.79M | $-11.54M |
| EBITDA Ratio | -58.05% | -613.06% | -596.03% | -659.61% | -1033.62% | -804.02% | 1316.04% | -467.64% | -812.70% | -921.17% | -771.77% | -818.27% | - | - | - | - | - | - | - | - |
| Operating Income | $-13.65M | $-30.00M | $-29.34M | $-28.37M | $-29.59M | $-27.23M | $-33.26M | $-20.44M | $-27.18M | $-27.15M | $-25.24M | $-24.80M | $-24.53M | $-22.68M | $-22.03M | $-16.83M | $-14.59M | $-13.71M | $-13.01M | $-11.73M |
| Operating Income Ratio | -60.37% | -613.06% | -607.37% | -672.96% | -1055.89% | -823.28% | 1340.67% | -396.78% | -831.29% | -934.53% | -781.12% | -826.50% | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $3.17M | $3.57M | $3.65M | $2.00M | $2.63M | $2.69M | $2.61M | $2.15M | $1.52M | $1.04M | $586.00K | $146.00K | $78.00K | $86.00K | $62.00K | $34.00K | $25.00K | $27.00K | $53.00K | $696.00K |
| Income Before Tax | $-10.48M | $-26.43M | $-25.70M | $-26.37M | $-26.96M | $-24.54M | $-30.65M | $-22.55M | $-25.66M | $-26.11M | $-24.65M | $-24.65M | $-24.45M | $-22.60M | $-21.97M | $-16.79M | $-14.56M | $-13.68M | $-12.96M | $-11.04M |
| Income Before Tax Ratio | -46.35% | -540.05% | -531.88% | -625.57% | -962.10% | -741.90% | 1235.55% | -437.60% | -784.80% | -898.83% | -762.98% | -821.63% | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $1.07M | $10.71M | $-3.29M | $-3.18M | $-4.25M | $-3.61M | $-2.03M | $-1.43M | $-250.00K | $-78.00K | $-44.00K | $-34.00K | $-254.00K | $-10.00K | $-245.00K | $-50.00K | $-674.00K |
| Net Income | $-10.48M | $-26.43M | $-25.70M | $-26.37M | $-26.96M | $-24.54M | $-30.65M | $-18.30M | $-22.05M | $-24.08M | $-23.22M | $-24.40M | $-24.45M | $-22.60M | $-21.97M | $-16.79M | $-14.56M | $-13.68M | $-12.96M | $-11.04M |
| Net Income Ratio | -46.35% | -540.05% | -531.88% | -625.57% | -962.10% | -741.90% | 1235.55% | -355.14% | -674.43% | -828.88% | -718.66% | -813.30% | - | - | - | - | - | - | - | - |
| EPS | $-0.19 | $-0.47 | $-0.46 | $-0.57 | $-0.60 | $-0.55 | $-0.69 | $-0.43 | $-0.56 | $-0.61 | $-0.59 | $-0.65 | $-0.66 | $-0.61 | $-0.60 | $-0.46 | $-0.44 | $-0.41 | $-0.39 | $-0.34 |
| EPS Diluted | $-0.19 | $-0.47 | $-0.46 | $-0.57 | $-0.60 | $-0.55 | $-0.69 | $-0.43 | $-0.56 | $-0.61 | $-0.59 | $-0.65 | $-0.66 | $-0.61 | $-0.60 | $-0.46 | $-0.44 | $-0.41 | $-0.39 | $-0.34 |
| Weighted Average Shares Outstanding | 54.01M | 56.34M | 55.77M | 46.25M | 44.96M | 44.27M | 44.19M | 42.54M | 39.43M | 39.42M | 39.26M | 37.45M | 36.84M | 36.76M | 36.71M | 36.64M | 33.27M | 33.27M | 33.05M | 32.90M |
| Weighted Average Shares Outstanding Diluted | 54.01M | 56.34M | 55.77M | 46.25M | 44.96M | 44.27M | 44.19M | 42.54M | 39.43M | 39.42M | 39.26M | 37.45M | 36.84M | 36.76M | 36.71M | 36.64M | 33.27M | 33.27M | 33.05M | 32.90M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $127.98M | $191.44M | $113.56M | $144.90M | $287.31M |
| Short Term Investments | $88.92M | $9.95M | $116.04M | $74.92M | $- |
| Cash and Short Term Investments | $216.90M | $201.39M | $229.59M | $219.81M | $287.31M |
| Net Receivables | $700.00K | $64.00K | $588.00K | $132.00K | $6.00K |
| Inventory | $- | $- | $10.93M | $- | $- |
| Other Current Assets | $15.16M | $13.88M | $13.89M | $9.28M | $6.62M |
| Total Current Assets | $232.76M | $215.34M | $244.07M | $229.22M | $293.93M |
| Property Plant Equipment Net | $8.25M | $12.43M | $11.43M | $9.08M | $3.79M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $569.00K | $569.00K | $205.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $30.55M | $569.00K | $- | $- | $- |
| Total Non-Current Assets | $38.80M | $13.00M | $12.00M | $9.65M | $4.00M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $271.56M | $228.34M | $256.07M | $238.87M | $297.93M |
| Account Payables | $2.50M | $1.70M | $766.00K | $2.38M | $1.50M |
| Short Term Debt | $2.32M | $2.39M | $2.36M | $1.51M | $1.07M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $18.99M | $15.31M | $14.88M | $12.71M | $-1.07M |
| Other Current Liabilities | $16.25M | $11.75M | $13.39M | $13.25M | $8.86M |
| Total Current Liabilities | $40.06M | $30.82M | $31.39M | $17.14M | $11.43M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $33.07M | $36.86M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-2.72M | $- | $- |
| Other Non-Current Liabilities | $2.48M | $4.88M | $2.97M | $3.95M | $422.00K |
| Total Non-Current Liabilities | $2.48M | $37.96M | $39.82M | $3.95M | $422.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $42.53M | $68.78M | $71.22M | $21.09M | $11.85M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K |
| Retained Earnings | $-490.83M | $-401.85M | $-297.15M | $-196.08M | $-110.28M |
| Accumulated Other Comprehensive Income Loss | $-151.00K | $-24.00K | $-1.18M | $-168.00K | $-0 |
| Other Total Stockholders Equity | $720.00M | $561.43M | $483.17M | $414.02M | $396.35M |
| Total Stockholders Equity | $229.02M | $159.56M | $184.85M | $217.78M | $286.08M |
| Total Equity | $229.02M | $159.56M | $184.85M | $217.78M | $286.08M |
| Total Liabilities and Stockholders Equity | $271.56M | $228.34M | $256.07M | $238.87M | $297.93M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $271.56M | $228.34M | $256.07M | $238.87M | $297.93M |
| Total Investments | $88.92M | $9.95M | $116.04M | $74.92M | $205.00K |
| Total Debt | $2.32M | $2.06M | $2.36M | $1.51M | $80.00K |
| Net Debt | $-125.66M | $-189.38M | $-111.20M | $-143.39M | $-287.23M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $127.98M | $150.02M | $193.55M | $178.58M | $191.44M | $189.98M | $192.06M | $190.34M | $113.56M | $113.40M | $67.75M | $84.11M | $144.90M | $149.04M | $169.07M | $267.51M | $287.31M | $191.46M | $201.93M | $211.29M |
| Short Term Investments | $88.92M | $89.18M | $88.51M | $- | $9.95M | $24.74M | $39.39M | $63.33M | $116.04M | $138.26M | $207.88M | $209.10M | $74.92M | $87.12M | $82.16M | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $216.90M | $239.20M | $282.06M | $178.58M | $201.39M | $214.72M | $231.45M | $253.67M | $229.59M | $251.66M | $275.63M | $293.22M | $219.81M | $236.16M | $251.23M | $267.51M | $287.31M | $191.46M | $201.93M | $211.29M |
| Net Receivables | $700.00K | $691.00K | $305.00K | $11.00K | $64.00K | $96.00K | $136.00K | $492.00K | $588.00K | $395.00K | $350.00K | $265.00K | $132.00K | $45.00K | $131.00K | $6.00K | $6.00K | $2.00K | $9.00K | $144.00K |
| Inventory | $- | $75.00K | $- | $- | $- | $10.94M | $10.95M | $10.19M | $10.93M | $- | $- | $- | $-132.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $15.16M | $13.65M | $14.71M | $14.28M | $13.88M | $15.21M | $14.65M | $16.07M | $13.89M | $25.10M | $26.36M | $24.58M | $9.28M | $8.73M | $8.88M | $7.78M | $6.62M | $3.99M | $3.60M | $8.68M |
| Total Current Assets | $232.76M | $253.61M | $296.99M | $192.87M | $215.34M | $230.02M | $246.23M | $270.24M | $244.07M | $264.60M | $289.16M | $305.77M | $229.22M | $244.93M | $260.23M | $275.30M | $293.93M | $195.46M | $205.54M | $215.77M |
| Property Plant Equipment Net | $8.25M | $9.26M | $10.27M | $11.34M | $12.43M | $9.30M | $10.12M | $10.99M | $11.43M | $12.46M | $11.70M | $9.60M | $9.08M | $8.27M | $4.14M | $3.56M | $3.79M | $4.27M | $4.46M | $4.86M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $29.82M | $29.95M | $494.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $569.00K | $75.00K | $58.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $721.00K | $494.00K | $-1 | $402.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $205.00K | $205.00K | $205.00K | $205.00K |
| Total Non-Current Assets | $38.80M | $39.71M | $10.76M | $12.31M | $13.00M | $9.87M | $10.69M | $11.56M | $12.00M | $13.03M | $12.27M | $10.17M | $9.65M | $8.84M | $4.22M | $3.61M | $4.00M | $4.48M | $4.67M | $5.07M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $271.56M | $293.32M | $307.76M | $205.18M | $228.34M | $239.89M | $256.92M | $281.80M | $256.07M | $277.63M | $301.43M | $315.94M | $238.87M | $253.77M | $264.45M | $278.91M | $297.93M | $199.94M | $210.21M | $220.84M |
| Account Payables | $2.50M | $2.48M | $3.94M | $2.10M | $1.70M | $3.08M | $1.56M | $4.30M | $766.00K | $1.91M | $3.60M | $3.33M | $2.38M | $655.00K | $963.00K | $1.50M | $1.50M | $1.09M | $904.00K | $1.78M |
| Short Term Debt | $2.32M | $2.30M | $2.28M | $2.21M | $2.06M | $2.50M | $2.45M | $2.40M | $2.36M | $2.31M | $2.08M | $1.53M | $1.51M | $1.43M | $592.00K | $- | $1.07M | $1.12M | $1.09M | $1.06M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $18.99M | $31.61M | $26.05M | $20.92M | $15.31M | $8.73M | $8.06M | $13.45M | $14.88M | $12.84M | $10.63M | $8.47M | $12.71M | $9.48M | $6.06M | $- | $-1.07M | $4.27M | $3.31M | $2.56M |
| Other Current Liabilities | $16.25M | $13.47M | $12.22M | $10.36M | $11.75M | $10.89M | $9.77M | $11.37M | $13.39M | $11.73M | $11.33M | $9.57M | $13.25M | $9.80M | $6.64M | $4.61M | $8.86M | $4.52M | $3.81M | $2.61M |
| Total Current Liabilities | $40.06M | $49.87M | $44.50M | $35.59M | $30.82M | $25.20M | $21.84M | $31.53M | $31.39M | $28.80M | $27.65M | $22.91M | $17.14M | $11.88M | $8.20M | $6.11M | $11.43M | $6.74M | $5.80M | $5.46M |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $20.00K | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $8.29M | $16.95M | $25.04M | $33.07M | $40.73M | $43.26M | $34.14M | $36.86M | $41.08M | $45.21M | $49.55M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $-4.77M | $-819.00K | $-1.46M | $-2.09M | $-2.72M | $-3.32M | $-3.91M | $-3.13M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $2.48M | $3.05M | $3.61M | $4.21M | $37.96M | $959.00K | $1.63M | $2.30M | $2.97M | $3.61M | $4.25M | $3.51M | $3.95M | $4.37M | $1.18M | $313.00K | $422.00K | $665.00K | $1.01M | $1.04M |
| Total Non-Current Liabilities | $2.48M | $11.34M | $20.55M | $29.25M | $37.96M | $41.69M | $44.89M | $36.45M | $39.82M | $44.69M | $49.46M | $53.06M | $3.95M | $4.37M | $1.18M | $333.00K | $422.00K | $665.00K | $1.01M | $1.04M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $42.53M | $61.21M | $65.05M | $64.84M | $68.78M | $66.89M | $66.72M | $67.97M | $71.22M | $73.48M | $77.11M | $75.96M | $21.09M | $16.26M | $9.38M | $6.44M | $11.85M | $7.40M | $6.81M | $6.50M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $-490.83M | $-480.35M | $-453.92M | $-428.22M | $-401.85M | $-374.89M | $-350.35M | $-319.69M | $-297.15M | $-271.50M | $-245.38M | $-220.73M | $-196.08M | $-171.63M | $-149.04M | $-127.07M | $-110.28M | $-95.72M | $-82.03M | $-69.07M |
| Accumulated Other Comprehensive Income Loss | $-151.00K | $166.00K | $-15.00K | $0 | $-24.00K | $-147.00K | $-379.00K | $-598.00K | $-1.18M | $-1.70M | $-1.28M | $-684.00K | $-168.00K | $-22.00K | $-42.00K | $-0 | $-0 | $-0 | $0 | $0 |
| Other Total Stockholders Equity | $720.00M | $712.29M | $696.64M | $568.56M | $561.43M | $548.03M | $540.92M | $534.11M | $483.17M | $477.34M | $470.98M | $461.39M | $414.02M | $409.17M | $404.14M | $399.53M | $396.35M | $288.25M | $285.43M | $283.41M |
| Total Stockholders Equity | $229.02M | $232.11M | $242.71M | $140.34M | $159.56M | $173.00M | $190.19M | $213.82M | $184.85M | $204.14M | $224.32M | $239.98M | $217.78M | $237.51M | $255.07M | $272.46M | $286.08M | $192.53M | $203.40M | $214.34M |
| Total Equity | $229.02M | $232.11M | $242.71M | $140.34M | $159.56M | $173.00M | $190.19M | $213.82M | $184.85M | $204.14M | $224.32M | $239.98M | $217.78M | $237.51M | $255.07M | $272.46M | $286.08M | $192.53M | $203.40M | $214.34M |
| Total Liabilities and Stockholders Equity | $271.56M | $293.32M | $307.76M | $205.18M | $228.34M | $239.89M | $256.92M | $281.80M | $256.07M | $277.63M | $301.43M | $315.94M | $238.87M | $253.77M | $264.45M | $278.91M | $297.93M | $199.94M | $210.21M | $220.84M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $271.56M | $293.32M | $307.76M | $205.18M | $228.34M | $239.89M | $256.92M | $281.80M | $256.07M | $277.63M | $301.43M | $315.94M | $238.87M | $253.77M | $264.45M | $278.91M | $297.93M | $199.94M | $210.21M | $220.84M |
| Total Investments | $118.74M | $119.14M | $89.00M | $569.00K | $10.52M | $24.74M | $39.39M | $63.33M | $116.04M | $138.26M | $207.88M | $209.10M | $74.92M | $87.12M | $82.16M | $58.00K | $- | $- | $- | $- |
| Total Debt | $2.32M | $2.30M | $5.83M | $6.34M | $6.83M | $2.50M | $2.45M | $2.40M | $2.36M | $2.31M | $2.08M | $1.53M | $1.51M | $1.43M | $592.00K | $20.00K | $1.07M | $1.12M | $1.09M | $1.06M |
| Net Debt | $-125.66M | $-147.72M | $-187.72M | $-172.24M | $-184.61M | $-187.48M | $-189.61M | $-187.94M | $-111.20M | $-111.08M | $-65.67M | $-82.58M | $-143.39M | $-147.61M | $-168.48M | $-267.49M | $-286.24M | $-190.34M | $-200.84M | $-210.22M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-88.98M | $-104.70M | $-101.07M | $-85.81M | $-52.24M |
| Depreciation and Amortization | $2.18M | $2.47M | $1.55M | $974.00K | $888.00K |
| Deferred Income Tax | $- | $- | $- | $172.00K | $3.00K |
| Stock Based Compensation | $27.47M | $25.26M | $22.85M | $16.45M | $5.77M |
| Change in Working Capital | $-28.14M | $-6.03M | $43.02M | $46.00K | $2.33M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $3.09M | $-3.21M | $121.00K | $2.90M | $5.20M |
| Other Working Capital | $-31.23M | $-2.82M | $42.90M | $-2.85M | $-2.88M |
| Other Non Cash Items | $623.00K | $1.94M | $1.78M | $1.26M | $1.04M |
| Net Cash Provided by Operating Activities | $-86.85M | $-81.07M | $-31.87M | $-66.91M | $-42.22M |
| Investments in Property Plant and Equipment | $-203.00K | $-1.62M | $-3.96M | $-1.20M | $-1.05M |
| Acquisitions Net | $- | $- | $45.34M | $75.23M | $- |
| Purchases of Investments | $-167.27M | $- | $-201.32M | $-87.23M | $- |
| Sales Maturities of Investments | $60.00M | $107.56M | $159.40M | $12.00M | $- |
| Other Investing Activities | $- | $- | $-45.34M | $-75.23M | $- |
| Net Cash Used for Investing Activities | $-107.47M | $105.95M | $-45.88M | $-76.43M | $-1.05M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $128.84M | $52.08M | $45.34M | $1.29M | $105.40M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.25M | $926.00K | $1.06M | $1.28M | $2.71M |
| Net Cash Used Provided by Financing Activities | $131.09M | $53.01M | $46.41M | $1.28M | $108.11M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-63.23M | $77.89M | $-31.34M | $-142.05M | $64.84M |
| Cash at End of Period | $128.78M | $192.01M | $114.12M | $145.46M | $287.51M |
| Cash at Beginning of Period | $192.01M | $114.12M | $145.46M | $287.51M | $222.68M |
| Operating Cash Flow | $-86.85M | $-81.07M | $-31.87M | $-66.91M | $-42.22M |
| Capital Expenditure | $-203.00K | $-1.62M | $-3.96M | $-1.20M | $-1.05M |
| Free Cash Flow | $-87.05M | $-82.68M | $-35.83M | $-68.11M | $-43.27M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-10.48M | $-26.43M | $-25.70M | $-26.37M | $-26.96M | $-24.54M | $-30.65M | $-22.55M | $-25.66M | $-26.11M | $-24.65M | $-24.65M | $-24.45M | $-22.60M | $-21.97M | $-16.79M | $-14.56M | $-13.68M | $-12.96M | $-11.04M |
| Depreciation and Amortization | $526.00K | $540.00K | $1.11M | $1.11M | $1.22M | $637.00K | $611.00K | $597.00K | $609.00K | $388.00K | $302.00K | $247.00K | $235.00K | $254.00K | $249.00K | $236.00K | $237.00K | $234.00K | $224.00K | $193.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-9.64M | $-121.00K | $-146.00K | $- | $- | $- | $- | $- | $57.00K | $49.00K | $37.00K | $29.00K | $- | $- | $- | $3.00K |
| Stock Based Compensation | $7.14M | $7.49M | $7.43M | $5.41M | $6.06M | $6.55M | $6.76M | $5.89M | $5.79M | $5.93M | $6.16M | $4.97M | $4.69M | $4.61M | $4.45M | $2.70M | $1.58M | $1.78M | $1.65M | $754.00K |
| Change in Working Capital | $-20.18M | $-3.24M | $-30.00K | $-4.69M | $-875.00K | $-351.00K | $1.07M | $-5.88M | $-3.51M | $-2.69M | $-2.08M | $51.31M | $2.83M | $2.68M | $1.12M | $-6.58M | $1.55M | $530.00K | $1.18M | $-935.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $-749.00K | $3.58M | $-1.92M | $-1.15M | $2.02M | $-4.43M | $351.00K | $-633.00K | $-1.35M | $754.00K | $-3.44M | $2.90M | $2.45M | $2.34M | $-5.50M | $5.20M | $- | $- | $-11.00K |
| Other Working Capital | $-20.18M | $-2.49M | $-3.61M | $-2.77M | $274.00K | $-2.37M | $5.50M | $-6.23M | $-2.88M | $-1.35M | $-2.83M | $54.75M | $-71.00K | $2.68M | $1.12M | $-1.08M | $-3.66M | $530.00K | $1.18M | $-924.00K |
| Other Non Cash Items | $-200.00K | $24.00K | $5.78M | $9.53M | $9.55M | $563.00K | $556.00K | $582.00K | $392.00K | $434.00K | $340.00K | $612.00K | $386.00K | $322.00K | $277.00K | $271.00K | $266.00K | $262.00K | $257.00K | $253.00K |
| Net Cash Provided by Operating Activities | $-23.19M | $-21.61M | $-17.48M | $-24.57M | $-20.65M | $-17.26M | $-21.80M | $-21.36M | $-22.37M | $-22.06M | $-19.93M | $32.49M | $-16.26M | $-14.68M | $-15.83M | $-20.14M | $-10.93M | $-10.87M | $-9.65M | $-10.77M |
| Investments in Property Plant and Equipment | $-42.00K | $-103.00K | $-46.00K | $-12.00K | $-229.00K | $-383.00K | $-839.00K | $-165.00K | $-409.00K | $-2.03M | $-682.00K | $-841.00K | $-203.00K | $-273.00K | $-520.00K | $-204.00K | $-90.00K | $-269.00K | $-81.00K | $-610.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $-45.34M | $-69.29M | $45.34M | $- | $70.44M | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-29.14M | $-49.90M | $-88.23M | $- | $- | $- | $- | $- | $4.87M | $-9.71M | $-52.54M | $-143.94M | $-82.23M | $-4.99M | $-82.23M | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $30.00M | $20.00M | $- | $10.00M | $15.00M | $15.00M | $24.31M | $53.25M | $18.03M | $79.00M | $53.37M | $9.00M | $12.00M | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-88.23M | $10.00M | $15.00M | $15.00M | $24.31M | $53.25M | $45.34M | $69.29M | $-45.34M | $-134.94M | $11.80M | $-4.99M | $-82.23M | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $819.00K | $-30.00M | $-88.28M | $9.99M | $14.77M | $14.62M | $23.47M | $53.09M | $22.49M | $67.26M | $146.00K | $-135.78M | $11.80M | $-5.26M | $-82.75M | $-204.00K | $-90.00K | $-269.00K | $-81.00K | $-610.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K |
| Common Stock Issued | $1.00K | $7.66M | $119.88M | $1.30M | $7.34M | $562.00K | $48.00K | $44.74M | $42.00K | $434.00K | $3.10M | $42.24M | $777.00K | $408.00K | $159.00K | $546.00K | $105.40M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $567.00K | $503.00K | $766.00K | $418.00K | $5.00K | $562.00K | $48.00K | $311.00K | $43.00K | $434.00K | $326.00K | $262.00K | $171.00K | $408.00K | $159.00K | $546.00K | $1.47M | $673.00K | $369.00K | $199.00K |
| Net Cash Used Provided by Financing Activities | $568.00K | $8.16M | $120.65M | $1.72M | $7.34M | $562.00K | $48.00K | $45.05M | $43.00K | $434.00K | $3.42M | $42.51M | $171.00K | $408.00K | $159.00K | $546.00K | $106.87M | $673.00K | $369.00K | $198.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $16.26M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-21.81M | $-42.97M | $14.97M | $-12.86M | $1.47M | $-2.08M | $1.72M | $76.78M | $160.00K | $45.64M | $-16.36M | $-60.78M | $-4.29M | $-19.54M | $-98.43M | $-19.79M | $95.85M | $-10.47M | $-9.36M | $-11.18M |
| Cash at End of Period | $128.78M | $150.59M | $193.55M | $178.58M | $191.44M | $190.55M | $192.63M | $190.91M | $114.12M | $113.97M | $68.32M | $84.68M | $145.46M | $149.75M | $169.29M | $267.72M | $287.51M | $191.67M | $202.13M | $211.49M |
| Cash at Beginning of Period | $150.59M | $193.55M | $178.58M | $191.44M | $189.98M | $192.63M | $190.91M | $114.12M | $113.97M | $68.32M | $84.68M | $145.46M | $149.75M | $169.29M | $267.72M | $287.51M | $191.67M | $202.13M | $211.49M | $222.68M |
| Operating Cash Flow | $-23.19M | $-21.61M | $-17.48M | $-24.57M | $-20.65M | $-17.26M | $-21.80M | $-21.36M | $-22.37M | $-22.06M | $-19.93M | $32.49M | $-16.26M | $-14.68M | $-15.83M | $-20.14M | $-10.93M | $-10.87M | $-9.65M | $-10.77M |
| Capital Expenditure | $-42.00K | $-103.00K | $-46.00K | $-12.00K | $-229.00K | $-383.00K | $-839.00K | $-165.00K | $-409.00K | $-2.03M | $-682.00K | $-841.00K | $-203.00K | $-273.00K | $-520.00K | $-204.00K | $-90.00K | $-269.00K | $-81.00K | $-610.00K |
| Free Cash Flow | $-23.23M | $-21.72M | $-17.52M | $-24.58M | $-20.88M | $-17.64M | $-22.64M | $-21.52M | $-22.78M | $-24.09M | $-20.61M | $31.65M | $-16.46M | $-14.96M | $-16.35M | $-20.34M | $-11.02M | $-11.14M | $-9.73M | $-11.38M |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
$9.56
Stock Price
$516.71M
Market Cap
128
Employees
Bedford, MA
Location
Revenue (FY 2024)
$36.55M
316.3% YoY
Net Income (FY 2024)
$-88.98M
15.0% YoY
EPS (FY 2024)
$-1.65
30.7% YoY
Free Cash Flow (FY 2024)
$-87.05M
-5.3% YoY
Profitability
Gross Margin
100.0%
Net Margin
-243.4%
ROE
-38.9%
ROA
-32.8%
Valuation
P/E Ratio
-6.69
P/S Ratio
16.30
EV/EBITDA
-4.64
Market Cap
$516.71M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-86.85M
-7.1% YoY
Free Cash Flow
$-87.05M
-5.3% YoY
Balance Sheet Summary
Total Assets
$271.56M
18.9% YoY
Total Debt
$2.32M
12.6% YoY
Shareholder Equity
$229.02M
16.9% YoY
Dividend Overview
No Dividend Data
Stoke Therapeutics, Inc. doesn't currently pay dividends.
Stoke Therapeutics Dividends
Explore Stoke Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Stoke Therapeutics News
Read the latest news about Stoke Therapeutics, including recent articles, headlines, and updates.
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tues.
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates. “Recent milestones – including Breakt.
Stoke Therapeutics Announces CEO Transition
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025. To.
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Wednesday, March 5, 2025 Time: 9:50 a.m. ET Leerink Partners Global Healthcare Conference Date: Monday, March 10, 2025 Time: 10:40 a.m. ET Live webcasts of each ev.
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges.
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT). A live audio webcast of the presentation will be available on the Investors & News section of Stoke's website at https://investor.stokether.
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced alignment with global regulatory agencies on the design of the Company's Phase 3 EMPEROR study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. Following successful interactions with the FDA, EMA and PMDA, the Company has finalized.
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced new data from an analysis of nine patients treated with an initial 2 or 3 doses of 70mg, followed by 45mg maintenance dosing in the Phase 1/2a and open-label extension (OLE) studies of zorevunersen. Substantial and durable reductions in convulsive seizure frequency were observed in these.
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analys.
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Date: Tuesday, September 10, 2024 Time: 12:00 p.m. ET 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 11:30 a.m.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for STOK.